{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=5", "query": { "condition": "AdverseEvent", "page": 5 }, "page_size": 10 }, "pagination": { "page": 5, "page_size": 10, "total_count": 927, "total_pages": 93, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=6&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=AdverseEvent&page=4&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T05:25:34.907Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06772623", "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Carcinoma", "c-MET" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Budigalimab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 252, "start_date": "2025-03-06", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 27, "location_summary": "Phoenix, Arizona • Fullerton, California • Oxnard, California + 24 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06772623" }, { "nct_id": "NCT00277173", "title": "Improving Geriatric Drug Safety in Underserved Practices", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiovascular Diseases" ], "interventions": [ { "name": "Adoption of Crew Resource Management approach", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Agency for Healthcare Research and Quality (AHRQ)", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 4800, "start_date": "2006-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-01-16", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00277173" }, { "nct_id": "NCT06318273", "title": "A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "ABBV-969", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 152, "start_date": "2024-03-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 9, "location_summary": "Duarte, California • San Francisco, California • New Haven, Connecticut + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Orlando", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06318273" }, { "nct_id": "NCT01924182", "title": "Intrathecal Morphine Compared to Conventional Medical Management for Pain Control and Opioid-related Side Effects", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Pain" ], "interventions": [ { "name": "SynchroMed Infusion System and Intrathecal Morphine Sulfate", "type": "DEVICE" }, { "name": "Conventional Medicine", "type": "OTHER" } ], "intervention_types": [ "DEVICE", "OTHER" ], "sponsor": "MedtronicNeuro", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2013-10", "completion_date": "2015-07", "has_results": true, "last_update_posted_date": "2018-03-29", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 6, "location_summary": "Homewood, Alabama • Napa, California • Walnut Creek, California + 3 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Napa", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01924182" }, { "nct_id": "NCT00002586", "title": "13-Cis Retinoic Acid With or Without Vitamin E for Prevention of Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Drug Toxicity", "Lung Cancer" ], "interventions": [ { "name": "13-cis retinoic acid", "type": "DRUG" }, { "name": "Tocopherol", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 96, "start_date": "1993-01", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2020-05-15", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 4, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002586" }, { "nct_id": "NCT06643494", "title": "Elimination of Prostate Cancer Treatment Side Effects Using a Nutraceutical", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "N-111", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "Optimal Health Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "40 Years to 80 Years · Male only" }, "enrollment_count": 100, "start_date": "2024-08-15", "completion_date": "2026-12-15", "has_results": false, "last_update_posted_date": "2025-03-11", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06643494" }, { "nct_id": "NCT01380197", "title": "Choosing Opioid Management for Pain and Analyzing Acute Chest Syndrome (ACS) Rates Equally", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pain", "Sickle Cell Disease" ], "interventions": [ { "name": "Morphine", "type": "DRUG" }, { "name": "Nubain", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Healthcare of Atlanta", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "19 Years", "sex": "ALL", "summary": "6 Years to 19 Years" }, "enrollment_count": 40, "start_date": "2010-05-26", "completion_date": "2016-10-18", "has_results": true, "last_update_posted_date": "2018-02-20", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01380197" }, { "nct_id": "NCT06211413", "title": "Hypertension and Arrhythmias in CLL Patients Treated With BTK Inhibitors", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Lymphocytic Leukemia", "Atrial Fibrillation", "Hypertension", "Cardiotoxicity" ], "interventions": [ { "name": "no intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 50, "start_date": "2024-02-07", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06211413" }, { "nct_id": "NCT05926024", "title": "Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Exercise Recall Patient Reported Outcomes", "type": "BEHAVIORAL" }, { "name": "Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes", "type": "BEHAVIORAL" }, { "name": "Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes", "type": "BEHAVIORAL" }, { "name": "Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a)", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12)", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes PROMIS", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes FACT-Endocrine Symptoms", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes Penn Arthralgia Aging Survey", "type": "BEHAVIORAL" }, { "name": "Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE)", "type": "BEHAVIORAL" }, { "name": "p16 tumor suppressor gene", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BEHAVIORAL", "DIAGNOSTIC_TEST" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": 253, "start_date": "2023-01-06", "completion_date": "2028-01-31", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05926024" }, { "nct_id": "NCT01250496", "title": "Study With Aminophylline to Attenuate of the Side Effects of Regadenoson", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Patients Being Assessed With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson, Lexiscan" ], "interventions": [ { "name": "Aminophylline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 248, "start_date": "2010-11", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-22T05:25:34.907Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01250496" } ] }